Drug Profile
Citicoline
Alternative Names: Alphcolin; Audes; CDP choline; CerAxon; Cytidil diphosphocholine; Hipercol; IP 302; Metanervon; Neurex; Neurox; Nicholin; Somazina; Startonyl; TrausanLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Takeda
- Developer Ferrer; Takeda
- Class Neuroprotectants; Nootropics; Pyrimidine nucleotides; Small molecules; Trimethyl ammonium compounds
- Mechanism of Action Hydroxy radical formation inhibitors; Phosphatidylcholine stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Brain injuries; Parkinson's disease; Stroke
Most Recent Events
- 27 Jan 2006 IVAX Corporation has been acquired by Teva Pharmaceutical Industries
- 27 Oct 2004 Citicoline has been licensed to IVAX Corporation in USA
- 04 Jul 2002 Indevus has signed a non-binding memorandum of agreement with a privately held biotechnology company for further development of citicoline in the US and Canada